Compare · QS vs TMO
QS vs TMO
Side-by-side comparison of QuantumScape Corporation (QS) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- QS operates in Miscellaneous, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $198.47B, about 32.6x QS ($6.09B).
- Over the past year, QS is down 40.7% and TMO is up 27.9% - TMO leads by 68.6 points.
- TMO has been more active in the news (9 items in the past 4 weeks vs 4 for QS).
- TMO has more recent analyst coverage (25 ratings vs 22 for QS).
- Company
- QuantumScape Corporation
- Thermo Fisher Scientific Inc
- Price
- $6.43+2.31%
- $534.57+1.11%
- Market cap
- $6.09B
- $198.47B
- 1M return
- -11.00%
- +12.38%
- 1Y return
- -40.69%
- +27.92%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 4
- 9
- Recent ratings
- 22
- 25
QuantumScape Corporation
QuantumScape Corporation, a development stage company, engages in the development and commercialization of solid-state lithium-metal batteries for electric vehicles and other applications. The company was founded in 2010 and is headquartered in San Jose, California.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest QS
- QuantumScape Announces Timing of Second Quarter 2026 Business Results and Webcast
- CHIEF TECHNOLOGY OFFICER Holme Timothy converted options into 137,245 shares and sold $999,566 worth of shares (137,245 units at $7.28) as part of a pre-agreed trading plan (SEC Form 4)
- CHIEF FINANCIAL OFFICER Hettrich Kevin sold $71,362 worth of shares (9,800 units at $7.28) as part of a pre-agreed trading plan, decreasing direct ownership by 0.54% to 1,816,257 units (SEC Form 4)
- CHIEF FINANCIAL OFFICER Hettrich Kevin sold $77,811 worth of shares (9,800 units at $7.94) as part of a pre-agreed trading plan, decreasing direct ownership by 0.53% to 1,826,057 units (SEC Form 4)
- QuantumScape Announces Agreement with Honda on Solid-State Battery Technology
- SEC Form 144 filed by QuantumScape Corporation
- Director Saluja Dipender was granted 24,183 shares, increasing direct ownership by 6% to 396,418 units (SEC Form 4)
- Director Segers Dennis was granted 24,183 shares, increasing direct ownership by 19% to 149,524 units (SEC Form 4)
- Director Ribar Geoffrey G was granted 24,183 shares, increasing direct ownership by 67% to 60,285 units (SEC Form 4)
- Director Niebergall Ross was granted 24,183 shares, increasing direct ownership by 51% to 71,558 units (SEC Form 4)
Latest TMO
- Thermo Fisher Scientific Announces Quarterly Dividend
- Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, July 23, 2026
- SEC Form 4 filed by Director Sperling Scott M
- SEC Form 4 filed by Director Keith R. Alexandra
- SEC Form 4 filed by Director Weisler Dion J
- SEC Form 4 filed by Director Lynch Karen S
- SEC Form 4 filed by Director Johnson Jennifer M
- Bernstein resumed coverage on Thermo Fisher with a new price target
- SEC Form 11-K filed by Thermo Fisher Scientific Inc
- Piper Sandler initiated coverage on Thermo Fisher with a new price target